| Identification | Back Directory | [Name]
KR-33494 | [CAS]
1021497-97-1 | [Synonyms]
KM-819
CS-2472
KR-33494
KR-33493
KR33494;KR 33494
4-(2-(4-bromophenylthio)acetamido)-1-phenethyl-1H-pyrazole-3-carboxylic acid
4-[2-(4-bromo-phenylsulfanyl)-acetylamino]-1-phenethyl-1H-pyrazole-3-carboxylic acid
4-[[2-[(4-Bromophenyl)thio]acetyl]amino]-1-(2-phenylethyl)-1H-pyrazole-3-carboxylic acid
1H-Pyrazole-3-carboxylic acid, 4-[[2-[(4-bromophenyl)thio]acetyl]amino]-1-(2-phenylethyl)- | [Molecular Formula]
C20H18BrN3O3S | [MDL Number]
MFCD30738005 | [MOL File]
1021497-97-1.mol | [Molecular Weight]
460.34 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:61.5(Max Conc. mg/mL);133.6(Max Conc. mM) | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
KR-33493 is a potent inhibitor of Fas-mediated cell death (FAF1). | [in vivo]
Body weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. The dose-normalized AUClast is not significantly different between the groups, suggesting that KR-33493 is governed by linear kinetics[1]. | [IC 50]
Fas | [storage]
Store at -20°C | [References]
[1] Jeong JW, et al. Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-parkinson's disease agent, after oral administration in rats and dogs. Regul Toxicol Pharmacol. 2016 Nov;81:387-396. DOI:10.1016/j.yrtph.2016.09.022 |
|
|